These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33525825)

  • 1. Molecular mechanisms of III-B CRISPR-Cas systems in archaea.
    Zhang Y; Lin J; Feng M; She Q
    Emerg Top Life Sci; 2018 Dec; 2(4):483-491. PubMed ID: 33525825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cmr1 enables efficient RNA and DNA interference of a III-B CRISPR-Cas system by binding to target RNA and crRNA.
    Li Y; Zhang Y; Lin J; Pan S; Han W; Peng N; Liang YX; She Q
    Nucleic Acids Res; 2017 Nov; 45(19):11305-11314. PubMed ID: 28977458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas adaptive immune systems in Sulfolobales: genetic studies and molecular mechanisms.
    Yu Z; Jiang S; Wang Y; Tian X; Zhao P; Xu J; Feng M; She Q
    Sci China Life Sci; 2021 May; 64(5):678-696. PubMed ID: 33140167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of CRISPR-Cas Type III prokaryotic defence systems.
    Molina R; Sofos N; Montoya G
    Curr Opin Struct Biol; 2020 Dec; 65():119-129. PubMed ID: 32712502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into the CRISPR-Cas-associated ribonuclease activity of Staphylococcus epidermidis Csm3 and Csm6.
    Zhao Y; Wang J; Sun Q; Dou C; Gu Y; Nie C; Zhu X; Wei Y; Cheng W
    Sci Bull (Beijing); 2018 Jun; 63(11):691-699. PubMed ID: 36658818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales.
    Zink IA; Wimmer E; Schleper C
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33172134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive search for accessory proteins encoded with archaeal and bacterial type III CRISPR-cas gene cassettes reveals 39 new cas gene families.
    Shah SA; Alkhnbashi OS; Behler J; Han W; She Q; Hess WR; Garrett RA; Backofen R
    RNA Biol; 2019 Apr; 16(4):530-542. PubMed ID: 29911924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR adaptive immune systems of Archaea.
    Vestergaard G; Garrett RA; Shah SA
    RNA Biol; 2014; 11(2):156-67. PubMed ID: 24531374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Type III CRISPR-Cas Immunity by an Archaeal Virus-Encoded Anti-CRISPR Protein.
    Bhoobalan-Chitty Y; Johansen TB; Di Cianni N; Peng X
    Cell; 2019 Oct; 179(2):448-458.e11. PubMed ID: 31564454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
    Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
    Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
    Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
    Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
    Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
    Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.
    Pan S; Li Q; Deng L; Jiang S; Jin X; Peng N; Liang Y; She Q; Li Y
    RNA Biol; 2019 Sep; 16(9):1166-1178. PubMed ID: 31096876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System.
    Liu TY; Iavarone AT; Doudna JA
    PLoS One; 2017; 12(1):e0170552. PubMed ID: 28114398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analyses of the CRISPR protein Csc2 reveal the RNA-binding interface of the type I-D Cas7 family.
    Hrle A; Maier LK; Sharma K; Ebert J; Basquin C; Urlaub H; Marchfelder A; Conti E
    RNA Biol; 2014; 11(8):1072-82. PubMed ID: 25483036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Cas8 in type I CRISPR interference.
    Cass SD; Haas KA; Stoll B; Alkhnbashi OS; Sharma K; Urlaub H; Backofen R; Marchfelder A; Bolt EL
    Biosci Rep; 2015 May; 35(3):. PubMed ID: 26182359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.